April 4, 2025
| Trial | GO44479 |
|---|---|
| Cancer Type | Pancreatic Cancer |
| Hospital(s) | Belfast City Hospital |
| Information | A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF ADJUVANT AUTOGENE CEVUMERAN PLUS ATEZOLIZUMAB AND mFOLFIRINOX VERSUS mFOLFIRINOX ALONE IN PATIENTS WITH RESECTED PANCREATIC DUCTAL ADENOCARCINOMA |